Therapeutic Nanocarriers Inhibit Chemotherapy-Induced Breast Cancer Metastasis
© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH..
Chemotherapy, although effective against primary tumors, may promote metastasis by causing the release of proinflammatory factors from damaged cells. Here, polymeric nanoparticles that deliver chemotherapeutics and scavenge proinflammatory factors simultaneously to inhibit chemotherapy-induced breast cancer metastasis are developed. The cationic nanoparticles can adsorb cell-free nucleic acids (cfNAs) based on charge-charge interaction, which downregulates the expression of Toll-like receptors and then reduces the secretion of inflammatory cytokines. Through in vitro structural optimization, cationic polyamidoamine (PAMAM) dendrimers modified with drug-binding dodecyl groups and diethylethanolamine surface groups (PAMAM-G3-C125 -DEEA20 ) exhibit the most desirable combination of nanoparticle size (≈140 nm), drug loading, cytotoxicity, cfNA binding, and anti-inflammatory activity. In the mouse models of breast cancer metastasis, paclitaxel-loaded nanoparticles reduce serum levels of cfNAs and inflammatory cytokines compared with paclitaxel treatment alone and inhibit both primary tumor growth and tumor metastasis. Additionally, no significant side effects are detected in the serum or major organs. These results provide a strategy to deliver chemotherapeutics to primary tumors while reducing the prometastatic effects of chemotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) - 9(2022), 33 vom: 05. Nov., Seite e2203949 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Tianyu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.11.2022 Date Revised 28.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/advs.202203949 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347355242 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347355242 | ||
| 003 | DE-627 | ||
| 005 | 20231226033627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/advs.202203949 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347355242 | ||
| 035 | |a (NLM)36220339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Tianyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Nanocarriers Inhibit Chemotherapy-Induced Breast Cancer Metastasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2022 | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH. | ||
| 520 | |a Chemotherapy, although effective against primary tumors, may promote metastasis by causing the release of proinflammatory factors from damaged cells. Here, polymeric nanoparticles that deliver chemotherapeutics and scavenge proinflammatory factors simultaneously to inhibit chemotherapy-induced breast cancer metastasis are developed. The cationic nanoparticles can adsorb cell-free nucleic acids (cfNAs) based on charge-charge interaction, which downregulates the expression of Toll-like receptors and then reduces the secretion of inflammatory cytokines. Through in vitro structural optimization, cationic polyamidoamine (PAMAM) dendrimers modified with drug-binding dodecyl groups and diethylethanolamine surface groups (PAMAM-G3-C125 -DEEA20 ) exhibit the most desirable combination of nanoparticle size (≈140 nm), drug loading, cytotoxicity, cfNA binding, and anti-inflammatory activity. In the mouse models of breast cancer metastasis, paclitaxel-loaded nanoparticles reduce serum levels of cfNAs and inflammatory cytokines compared with paclitaxel treatment alone and inhibit both primary tumor growth and tumor metastasis. Additionally, no significant side effects are detected in the serum or major organs. These results provide a strategy to deliver chemotherapeutics to primary tumors while reducing the prometastatic effects of chemotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a cell-free nucleic acid | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a nanocarrier | |
| 650 | 4 | |a scavenger | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 650 | 7 | |a Poly(amidoamine) |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Akinade, Tolulope |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hongxia |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Qisong |e verfasserin |4 aut | |
| 700 | 1 | |a He, Siyu |e verfasserin |4 aut | |
| 700 | 1 | |a Rinebold, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Valencia Salazar, Luis E |e verfasserin |4 aut | |
| 700 | 1 | |a Bhansali, Divya |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Yiling |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Jinzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Dalerba, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Kam W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced science (Weinheim, Baden-Wurttemberg, Germany) |d 2014 |g 9(2022), 33 vom: 05. Nov., Seite e2203949 |w (DE-627)NLM252851455 |x 2198-3844 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:33 |g day:05 |g month:11 |g pages:e2203949 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/advs.202203949 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 33 |b 05 |c 11 |h e2203949 | ||